Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

GE Healthcare Launches Modular Biopharmaceutical Factory, KUBio

Published: Tuesday, January 15, 2013
Last Updated: Tuesday, January 15, 2013
Bookmark and Share
Innovative approach will save biopharmaceutical manufacturers time and money.

GE Healthcare has introduced KUBio™, an innovative off-the-shelf, modular factory designed to save manufacturers of biopharmaceuticals both time and money.

KUBio’s pre-made modules, which are assembled at a customer’s chosen site to make a fully functional ready-to-run bioprocessing facility, are significantly faster to install than constructing a traditional factory.

The modules are equipped with GE Healthcare’s world-class technologies for the start-to-finish manufacture of biopharmaceuticals.

Worldwide demand for biopharmaceuticals - such as antibodies for the treatment of cancer and rheumatoid arthritis, as well as the new generation of innovative vaccines - is increasing dramatically, driven by the global ageing population, rising obesity levels and the global effort to reduce the incidence of vaccine preventable diseases.

KUBio will help manufacturers to respond to local healthcare needs and bring these potentially life-saving treatments to market more quickly.

KUBio is a fully functional off-the-shelf bioprocessing facility specifically designed to meet cGMP requirements while optimizing manufacturing flexibility and productivity.

The 1200m2 facility is pre-fabricated and delivered with a complete ready-to-use production line, based on GE Healthcare’s Ready-to-Process™ single-use technologies.

With a total planning, delivery and construction time of 14 - 18 months, compared to the traditional 24 - 36 months, both time-to-market and level of capital investment are significantly reduced.

The first modular facilities to be introduced will be configured for the manufacture of monoclonal antibodies. GE Healthcare also plans to introduce modules for the manufacture of other biopharmaceuticals.

“KUBio is a totally new approach to the manufacture of biopharmaceuticals, bringing our customers a greatly simplified way to build their production capacity,” said Olivier Loeillot, General Manager of Enterprise Solutions, GE Healthcare Life Sciences.

Loeillot continued, “With KUBio our customers will be able to cut months off the typical construction time, and greatly streamline the whole construction process. We’re already seeing interest from a wide range of customers, from governments wanting to develop in-country manufacturing capability right through to pharmaceutical companies wanting to expand production capacity in new locations. KUBio is an industry game-changer that will help them do just that.”

The introduction of KUBio expands GE Healthcare’s broad offering of world-class tools, technologies and services for the biopharmaceutical manufacturing industry, allowing customers to benefit from a wide range of solutions that can be tailored to meet specific needs, from pilot to commercial scale.

GE Healthcare’s start-to-finish technologies and services include Fast Trak training, PAA cell culture media, ReadyToProcess single use technologies, specialist purification media and Xcellerex biomanufacturing systems.

KUBio aligns with GE’s healthymagination initiative which focuses on reducing cost, increasing access and improving quality in healthcare.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GE Healthcare Opens USD 7.4 Million APAC Fast Trak Center in South Korea
Center will support South Korea’s rapidly expanding biopharmaceutical industry, helping manufacturers increase production efficiency and speed to market.
Thursday, September 29, 2016
GE to Invest $150M in Biopharma Manufacturing
GE is to invest in a biopharmaceutical manufacturing campus in Cork, Ireland, and establish advanced manufacturing training centre at NIBRT.
Tuesday, September 20, 2016
GE Healthcare, STEMCELL Technologies Announce Agreement
Collaboration aims to provide T-Cell reagents for commercial-scale cell therapy production.
Wednesday, August 24, 2016
GE Healthcare, Sealed Air Announce Agreement
Collaboration aims to deliver film for single-use bioprocess systems.
Thursday, August 18, 2016
GE Healthcare Investing in Cures for Cancer
GE’s acquisition of Biosafe Group SA further develops integrated cell therapy and regenerative medicine enabling development and patient access to innovative therapies.
Wednesday, July 13, 2016
GE Healthcare Expands European Capabilities
Expansion will see large volume sterile liquid handling capacity doubled.
Tuesday, April 12, 2016
BeiGene Selects GE’s FlexFactory™ Biomanufacturing Platform
Facility will manufacture biologics for clinical trials.
Wednesday, December 16, 2015
GE Healthcare Life Sciences and Promosome Sign Licensing Agreement
Innovative mammalian cell line development technologies that show promise for increasing manufacturing efficiency of vital biopharmaceuticals.
Tuesday, April 29, 2014
GE Acquires Strategic Assets from Thermo
GE to acquire cell culture media and sera, gene modulation and magnetic beads businesses.
Monday, January 06, 2014
iBio, Inc. and GE Healthcare Form New Global Alliance
Companies to commercialize plant-based technologies for biopharmaceutical and vaccine manufacture.
Thursday, December 27, 2012
GE Healthcare Expands Shanghai Fast Trak Training Center
Expansion adds IN Cell, Biacore and DeltaVision technologies for drug discovery and development.
Monday, September 24, 2012
GE Healthcare Offers Fast Trak Training in Singapore
Fast Trak training and education courses provide practical training in the latest technologies and strategies for bioprocessing.
Tuesday, June 05, 2012
Karolinska University Hospital and GE Healthcare Collaborate to Advance Technologies for Cell Therapy
Pioneering three-year study will investigate technology and workflow needs in a clinical setting.
Wednesday, May 23, 2012
GE Healthcare to acquire Xcellerex Inc.
Addition of high growth company builds integrated, start-to-finish industry offering, focused on lowering costs, increasing productivity and reducing time to market.
Thursday, March 08, 2012
GE Healthcare and Neste Jacobs Form Strategic Alliance
Alliance will help healthcare providers worldwide increase access to life-saving treatments.
Tuesday, January 03, 2012
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
The Power Of Orthogonality In Assessing The Stability Of Biopharmaceuticals
By utilizing orthogonal techniques, researchers can maximize the secure application of all analytical results generated.
Dysfunction in Neuronal Transport Mechanism Linked to Alzheimer’s
Findings confirm mutation-caused problem but also reveal a new therapeutic target.
New Antibody Therapy Permanently Blocks SIV Infection
An international research team has developed an effective treatment strategy against the HIV-like Simian Immunodeficiency Virus (SIV) in rhesus macaques.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
DNA Vaccines Protect Monkeys Against Zika Virus
Two experimental Zika virus DNA vaccines developed by NIH scientists protected monkeys against Zika infection.
Rare Flu-Thwarting Mutation Discovered
Study finds protein mutation, that is encoded by influenza, causes the virus to lose any defence against the immune system.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos